SYNAPTICA BIO

PHARMA/LIFE SCIENCE

Ari Dworsky

ABOUT SYNAPTICA BIO

At Synaptica Bio, we are pioneering a new era in psychiatric and neuromodulation care through the development of safe, effective, and scientifically validated therapeutics integrated with emerging medical technology.

Our mission is to revolutionize new treatments by advancing next-generation compounds designed to address unmet needs of patients who have not responded to conventional therapies.

We believe that true innovation lies at the intersection of neuroscience, pharmacology, and patient-centric design. By harnessing the therapeutic potential of psychoactive derivatives to target new molecular structures, we aim not only to transform individual lives but also incorporate MedTech to support long-term treatment plans.

Our vision is bold: to redefine the standard of care in psychiatry by delivering novel, accessible treatments that are paired with technology to offer lasting relief and renewed hope for patients worldwide



BUSINESS MODEL CANVA

Key Partnerships

- Multidisciplinary Association for Psychedelic Studies (MAPS)
- American Psychiatric Association
- Anxiety and Depression Association of America
- American PTSD Association
- FDA & EMA
- Andrew Huberman Lab /Podcast
- Neil deGrasse Tyson Star Talk
- Biotech Hangout Podcast
- John Hopkins Research & University of Columbia

Key Activities

- Active in acquiring NIH and Federal Research Grants under Psychiatric Treatment
- Create Multi-organizational research team collaborating on one project within scientific area of expertise

Key Resources

- Patent Drug Candidates that are derived from existing psychedelic structure for psychiatric indications
- Plan to collaborate with other organizations to find other indications in which psychedelics can be medically beneficial

Value Proposition

- We are looking to enter the neuroscience and psychiatric space to offer innovative psychedelic treatments for growing unmet needs of psychiatric conditions.
- Our organizational goal is to get psychedelic therapies to market and provide higher level of efficacy in comparison to existing treatment options for ADD, ADHD, MDD, PTSD/CPTSD, and many other psychiatric conditions
- With our team of neuroscience and chemical experts, we inspire to drive change in a new market space

Customer Relationships

- We are aiming to break into the market by mirroring the zeitgeist of the current generation. We want to use popular social platforms and academic spaces to distribute information regarding efficacy and safety of psychedelics. Our marketing strategy would be driving the idea to become innovators of change.

Channels

- Our organization would offer in patient services as partnered psychiatric hospitals and centers for patients in critical need.
- Our services would also extend to outpatient visits for psychedelic prescriptions and pharmaceutical distribution of non-hallucinogenic psychedelics

Customer Segments

- Anxiety Disorders
  - Agoraphobia
  - GAD
  - Panic Disorder
  - SAD
  - Phobias
  - Postpartum
- Mood Disorders (Depression)
  - MDD
  - Dysthymia
  - Postpartum
  - Seasonal affective Disorder
  - Bipolar
- Mood Disorder (Bipolar)
  - Hypomanic
  - Manic
  - Mixed
  - Cyclothymic
- Substance Related Disorders
  - Alcohol
  - Opioid
  - Substance
- Stress-related Disorders
  - PTSD
- Neurodevelopmental disorders
  - ADHD
  - Autism Spectrum Disorder
  - Intellectual Disability

Cost Structure

- Our cost structure early on will be highly dependent on equity raised through venture capital, angel investors, and private equity. We would offer a solid financial position in the firm with a 10-20% of share ownership.
- Overtime, we aim to expand our capital structure to leverage non-organic streams of financing external to the organization such as funds raised through bonds, loans, and notes.
- Finally, we will aim to enter IPO upon clinical trial success to finance major business development with expansion into clinical centers, in-patient hospitals, and manufacturing facilities.

Revenue Stream

- Our primary revenue streams at the early stages of our company will be heavily reliant on research grants that will provide the ability to fund laboratory activity and employee payroll
- Once a psychedelic candidate has passed FDA Clinical Trials and has an approved NDA, revenue growth will exponentially increase as insurance providers, private and government, cover prescriptions and treatment for the patient population.
- Finally, when our services have fully expanded across pharmaceutical manufacturing and in/outpatient care, revenue streams will provide substantial enterprise value through growing cash flows.

STRATEGIC PLAN

BUSINESS DEVELOPMENT OVERVIEW

EARLY PHASE

"FOUNDATION AND VISION"

In the foundational phase, **Synaptica Bio** will establish its corporate entity and lay the groundwork for long-term growth through team-building and phase-gated R&D planning.

- **Legal Formation & Infrastructure:** Formally register as a Limited Liability Company (LLC) and build essential operational infrastructure.
- **Talent Acquisition:** Assemble an advisory network of leading experts in psychiatry, neuroscience, and regulatory affairs. All collaborators will operate under NDAs to protect IP and proprietary strategy.
- **Core Team Development:** Recruit a results-driven executive and scientific leadership team with deep experience in biotech innovation, clinical research, and commercialization.
- **Pipeline Exploration:** Begin evaluating a targeted portfolio of psychedelic-derived compounds, prioritizing those with compelling preclinical data and a strong scientific rationale for psychiatric indications.
- **Regulatory Engagement:** Initiate early communications with the FDA to align on regulatory pathways and obtain necessary approvals for investigational testing.
- **Capital Strategy:** With a validated lead candidate and a clear regulatory plan, we will engage venture capital firms and strategic investors to secure seed funding and support clinical advancement.

MID-LEVEL PHASE

"TRANSFORMATION AND GROWTH"

With secured funding to support initial capital (CAPEX) and operational expenditures (OPEX), **Synaptica** will transition into a phase of rapid growth and organizational maturity, building toward clinical readiness.

- **Strategic Team Deployment:** Design collaborative teams to actively gather market intelligence to refine product-market fit, identify unmet needs, and uncover key growth opportunities across psychiatric and neurodegenerative therapeutic areas.
- **R&D Advancement:** Scientific teams will focus on completing preclinical studies to support an Investigational New Drug (IND) application, prioritizing safety, efficacy, and translational potential.
- **Intellectual Property & Legal Strategy:** Our legal division will manage IP protection through continuous patent filings for novel psychoactive derivatives, ensuring a robust and defensible portfolio.
- **Regulatory Alignment:** Regulatory affairs will maintain proactive engagement with the FDA to secure necessary clearances for clinical advancement.
- **Operational Scaling:** The business development team will pursue strategic partnerships and explore acquisition or collaboration opportunities to secure manufacturing capabilities and streamline the supply chain.
- **Clinical Development Transition:** With research validated and infrastructure in place, Synaptica will initiate preparations for Phase I human trials through partnerships with academic research hospitals and clinical organizations, enabling a seamless shift into a clinically driven operation.

END PHASE

"PARTNERSHIP AND PERPETUITY"

Following successful completion of Phase I–III clinical trials and the submission of a New Drug Application (NDA), **Synaptica Bio** will be positioned to transition into a commercial-stage company.

- **Regulatory Milestone & Market Entry:** Upon FDA approval, Synaptica will launch its lead pharmaceutical candidates, addressing a wide spectrum of psychiatric disorders, including anxiety, depression, PTSD, mood, and cognitive-related conditions outlined in the DSM-5.
- **Strategic Exit Planning (IPO vs. M&A):** At this stage, Synaptica will evaluate strategic exit opportunities, whether through an Initial Public Offering (IPO) to unlock long-term equity value, or a merger or acquisition (M&A) by a global pharmaceutical partner to accelerate scale and distribution.
- **Commercial Launch & Revenue Generation:** We will activate a targeted commercialization strategy aimed at high-impact market segments, leveraging strategic partnerships, licensing opportunities, and distribution networks to drive sustained revenue.
- **Reputation & Advocacy:** Our ongoing engagement with thought leaders, mental health advocates, and high-profile figures will strengthen Synaptica' visibility, shape public discourse, and foster trust in psychoactive-based treatments.
- **Sustainable Growth & Pipeline Expansion:** With a foundation of scientific credibility and commercial success, Synaptica will reinvest in R&D, advance new pipeline candidates, and explore global expansion, ensuring lasting value for patients, partners, and shareholders.

THANK YOU

Ari Dworsky

612-559-5880

adworsky1@luc.edu

Ari Dworsky | M.Sc, MBA Graduate Student in Pharmacology